Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARTHUR R MABAQUIAO

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1730271933
CMS profile
351444
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$22,019.78

247 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARTHUR R MABAQUIAO

NPI 1730271933 · CMS profile ID 351444

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARTHUR R MABAQUIAO, NPI 1730271933, CMS profile ID 351444. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ARTHUR R MABAQUIAO, NPI 1730271933, CMS profile ID 351444. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ARTHUR R MABAQUIAO, NPI 1730271933, CMS profile ID 351444, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

247 matching records · $22,019.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 247 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 247.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $8.6510/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721418777 CMS
Horizon Therapeutics plc $4.2710/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721418779 CMS
Amgen Inc. $18.3910/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918469 CMS
Amgen Inc. $22.3410/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918465 CMS
GlaxoSmithKline, LLC. $13.8610/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738513293 CMS
GENZYME CORPORATION $20.2210/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744151251 CMS
AbbVie Inc. $17.7810/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722009753 CMS
Amgen Inc. $124.2610/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741369137 CMS
FIDIA PHARMA USA INC. $24.5310/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748296455 CMS
Horizon Therapeutics plc $2.2410/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721418775 CMS
UCB, Inc. $15.1610/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746089111 CMS
Actelion Pharmaceuticals US, Inc. $10.9810/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034797 CMS
Janssen Biotech, Inc. $23.1810/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034879 CMS
Janssen Biotech, Inc. $21.0010/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034875 CMS
Amgen Inc. $22.1610/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918455 CMS
Novartis Pharmaceuticals Corporation $19.4210/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725998393 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.8210/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747259017 CMS
Amgen Inc. $30.1810/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918485 CMS
CSL Behring $13.0710/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728951293 CMS
AbbVie Inc. $15.1109/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722009749 CMS
Horizon Therapeutics plc $19.3709/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721418773 CMS
GlaxoSmithKline, LLC. $43.7509/25/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738513539 CMS
GlaxoSmithKline, LLC. $13.7509/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738823241 CMS
Eisai Inc. $14.3309/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751229399 CMS
Horizon Therapeutics plc $17.7309/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721418771 CMS
Amgen Inc. $18.6409/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741369133 CMS
Novartis Pharmaceuticals Corporation $17.1209/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725998385 CMS
PFIZER INC. $20.9909/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743366063 CMS
AbbVie Inc. $21.6309/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722009745 CMS
Amgen Inc. $16.1909/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918453 CMS
Novartis Pharmaceuticals Corporation $19.9209/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725998389 CMS
Mallinckrodt Hospital Products Inc. $34.9609/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751708347 CMS
Janssen Scientific Affairs, LLC $13.0309/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034893 CMS
Actelion Pharmaceuticals US, Inc. $17.3409/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034793 CMS
AbbVie Inc. $19.9609/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722009743 CMS
Amgen Inc. $17.9509/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918449 CMS
Amgen Inc. $8.7109/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918481 CMS
Janssen Biotech, Inc. $7.4109/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034861 CMS
Janssen Biotech, Inc. $0.9309/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719034865 CMS
Mallinckrodt Hospital Products Inc. $27.0609/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751708345 CMS
Novartis Pharmaceuticals Corporation $25.0008/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725998381 CMS
Horizon Therapeutics plc $7.7608/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721418769 CMS
PFIZER INC. $17.5808/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743364595 CMS
AbbVie Inc. $22.7208/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722009739 CMS
Alexion Pharmaceuticals, Inc. $17.8908/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726629195 CMS
UCB, Inc. $37.7508/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746091739 CMS
Amgen Inc. $8.6008/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918507 CMS
Amgen Inc. $17.9308/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740918447 CMS
Mallinckrodt Hospital Products Inc. $27.1608/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751708343 CMS
GlaxoSmithKline, LLC. $34.4608/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738854023 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $48,030.59 275
PY2020 $22,019.78 247
PY2021 $28,292.13 328
PY2022 $21,900.80 297
PY2023 $24,769.66 363
PY2024 $34,564.76 375
PY2025 $28,997.98 363

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $287,193.16 52
PY2024 Principal investigator $78,438.66 21
PY2023 Principal investigator $100,092.49 50
PY2022 Principal investigator $78,023.62 39
PY2021 Principal investigator $191,358.52 46
PY2020 Principal investigator $201,814.43 53
PY2019 Principal investigator $452,493.85 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 12/19/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223290024
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,608.70 12/17/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289778
Principal investigator 1 Mesoblast, Inc. $8,315.00 12/05/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251880
Principal investigator 1 ABBVIE INC. $1,300.99 12/04/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202528884
Principal investigator 1 ABBVIE INC. $6,322.95 12/04/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,103.05 12/01/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,936.25 11/19/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288493
Principal investigator 1 ABBVIE INC. $155.25 11/18/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524527
Principal investigator 1 ABBVIE INC. $750.60 11/18/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524539
Principal investigator 1 Mesoblast, Inc. $22,432.00 11/14/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251878
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $438.00 11/12/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 11/12/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288249
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $134.00 11/12/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288251
Principal investigator 1 ABBVIE INC. $8,590.20 11/05/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522035
Principal investigator 1 ABBVIE INC. $186.30 10/16/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202517185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,517.75 10/15/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286951
Principal investigator 1 ABBVIE INC. $14,024.00 10/09/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202514729
Principal investigator 1 Mesoblast, Inc. $13,284.00 10/03/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251868
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,551.50 10/03/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CEN
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,737.80 09/24/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285840
Principal investigator 1 Mesoblast, Inc. $26,864.00 09/12/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251960
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $292.00 09/10/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285255
Principal investigator 1 ABBVIE INC. $1,584.39 09/04/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202509190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,551.50 08/27/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284621
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,153.25 08/27/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284623
Principal investigator 1 Janssen Research & Development, LLC $15,000.00 08/15/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER L LC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175426127
Principal investigator 1 ABBVIE INC. $1,398.60 08/14/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504873
Principal investigator 1 Mesoblast, Inc. $15,404.00 08/08/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251866
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,187.05 08/01/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283443
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 07/24/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER L LC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175426133
Principal investigator 1 ABBVIE INC. $6,375.00 07/10/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202497906
Principal investigator 1 Mesoblast, Inc. $7,017.00 07/03/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251872
Principal investigator 1 ABBVIE INC. $1,300.99 07/02/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202495147
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 06/20/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281704
Principal investigator 1 Mesoblast, Inc. $4,083.00 06/06/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251876
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 05/28/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280474
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,500.00 05/16/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279912
Principal investigator 1 Mesoblast, Inc. $250.00 05/09/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251874
Principal investigator 1 ABBVIE INC. $4,220.10 05/07/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483445
Principal investigator 1 Mesoblast, Inc. $1,952.00 04/18/2025 Non-covered Recipient Entity
Advanced Clinical Research Center
MSB-DR004 No dispute reported 06/30/2026 1228251870
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 04/16/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278126
Principal investigator 1 Eli Lilly and Company $6,532.00 04/11/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873553
Principal investigator 1 ABBVIE INC. $1,300.99 04/03/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202469331
Principal investigator 1 ABBVIE INC. $2,600.00 04/01/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202467760
Principal investigator 1 ABBVIE INC. $585.30 03/27/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202466937
Principal investigator 1 ABBVIE INC. $355.80 03/27/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202466988
Principal investigator 1 ABBVIE INC. $14,000.00 03/07/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202461561
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,100.00 02/27/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER TRIWEST RESEARCH ASSOCIATES
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis No dispute reported 06/30/2026 1190312633
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,895.53 02/26/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis No dispute reported 06/30/2026 1185551929
Principal investigator 1 Novartis Pharmaceuticals Corporation $243.01 02/10/2025 Non-covered Recipient Entity
TRIWEST RESEARCH ASSOCIATES
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis No dispute reported 06/30/2026 1190303867
Principal investigator 1 Novartis Pharmaceuticals Corporation $58.32 01/15/2025 Non-covered Recipient Entity
TRIWEST RESERACH ASSOCIATES
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190303811
Principal investigator 1 ABBVIE INC. $1,300.99 01/02/2025 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH CENTER
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202434184